Related references
Note: Only part of the references are listed.Clinical development of metabolic inhibitors for oncology
Kathryn M. Lemberg et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement
Jesse Alt et al.
CURRENT DRUG METABOLISM (2021)
The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Kathryn M. Lemberg et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
Nikita S. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
Anas Najjar et al.
MOLECULES (2020)
Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 Mice
Kristen R. Hollinger et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Min-Hee Oh et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Tumor-Targeted Delivery of 6-Diazo-5-oxo-L-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs
Lukas Tenora et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Prodrugs for targeted cancer therapy
Carla Souza et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Robert D. Leone et al.
SCIENCE (2019)
Targeting Glutamine Metabolism for Cancer Treatment
Yeon-Kyung Choi et al.
BIOMOLECULES & THERAPEUTICS (2018)
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs
Sarah C. Zimmermann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The expanding role of prodrugs in contemporary drug design and development
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy
Lingling Shan et al.
THERANOSTICS (2018)
We're Not DON Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine
Kathryn M. Lemberg et al.
MOLECULAR CANCER THERAPEUTICS (2018)
N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-L-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders
Michael T. Nedelcovych et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents
Huining He et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Discovery of 6-Diazo-5-oxo-L-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma
Rana Rais et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Tenofovir alafenamide for HIV infection: is less more?
Christina Wyatt et al.
LANCET (2015)
Small molecule glutaminase inhibitors block glutamate release from stimulated microglia
Ajit G. Thomas et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors
Ajit G. Thomas et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)
Yan-Jun Zhong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Christopher T. Hensley et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease
Nobuhide Ueki et al.
NATURE COMMUNICATIONS (2013)
Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis An experimental study
Li-Hua Shao et al.
CANCER (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Anne Le et al.
CELL METABOLISM (2012)
Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism
K. Thangavelu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Protease-Activated Drug Development
Ki Young Choi et al.
THERANOSTICS (2012)
Prodrugs for improving tumor targetability and efficiency
Rubi Mahato et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Production of ES1 Plasma Carboxylesterase Knockout Mice for Toxicity Studies
Ellen G. Duysen et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2011)
Prodrugs-from Serendipity to Rational Design
Kristiina M. Huttunen et al.
PHARMACOLOGICAL REVIEWS (2011)
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model
Laura M. Shelton et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
R. J. DeBerardinis et al.
ONCOGENE (2010)
Glutamine addiction: a new therapeutic target in cancer
David R. Wise et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Organization of GC/MS and LC/MS metabolomics data into chemical libraries
Corey D DeHaven et al.
Journal of Cheminformatics (2010)
Targeting metabolic transformation for cancer therapy
Daniel A. Tennant et al.
NATURE REVIEWS CANCER (2010)
Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis
Ralph J. DeBerardinis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Anticancer carrier-linked prodrugs in clinical trials
Felix Kratz et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Enzymes involved in the bioconversion of ester-based prodrugs
Bianca M. Liederer et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma
B Li et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate
IG Kirwan et al.
CLINICAL CANCER RESEARCH (2004)
Multiple roles for cysteine cathepsins in cancer
JA Joyce et al.
CELL CYCLE (2004)
Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug
PD Senter et al.
BIOCONJUGATE CHEMISTRY (2001)
Clinical pharmacokinetics of capecitabine
B Reigner et al.
CLINICAL PHARMACOKINETICS (2001)
Share Paper
